 |
|
Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery
Dennis T. Mangano, PhD, MD;
Yinghui Miao, MD, MPH;
Alain Vuylsteke, MD;
Iulia C. Tudor, PhD;
Rajiv Juneja, MD;
Daniela Filipescu, MD;
Andreas Hoeft, MD;
Manuel L. Fontes, MD;
Zak Hillel, PhD, MD;
Elisabeth Ott, MD;
Tatiana Titov, MD, PhD;
Cynthia Dietzel, MD;
Jack Levin, MD; for the Investigators of The Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation
JAMA. 2007;297:471-479.
Context Acute safety concerns have been raised recently regarding certain hemorrhage-sparing medications commonly used in cardiac surgery. However, no comprehensive data exist regarding their associations with long-term mortality.
Objective To contrast long-term all-cause mortality in patients undergoing coronary artery bypass graft (CABG) surgery according to use of 2 lysine analog antifibrinolytics (aminocaproic acid and tranexamic acid), the serine protease inhibitor aprotinin, or no antibleeding agent.
Design, Setting, and Participants Observational study of mortality conducted between November 11, 1996, and December 7, 2006. Following index hospitalization (4374 patients; 69 medical centers), survival was prospectively assessed at 6 weeks, 6 months, and annually for 5 years after CABG surgery among 3876 patients enrolled in a 62-center international cohort study. The associations of survival with hemorrhage-sparing medications were compared using multivariable analyses including propensity adjustments.
Main Outcome Measure Death (all-cause) over 5 years.
Results Aprotinin treatment (223 deaths among 1072 patients [20.8% 5-year mortality]) was associated with significantly increased mortality compared with control (128 deaths among 1009 patients [12.7%]; covariate adjusted hazard ratio for death, 1.48; 95% confidence interval, 1.19-1.85), whereas neither aminocaproic acid (132 deaths among 834 patients [15.8%]; adjusted hazard ratio for death, 1.03; 95% confidence interval, 0.80-1.33) nor tranexamic acid (65 deaths among 442 patients [14.7%]; adjusted hazard ratio for death, 1.07; 95% confidence interval, 0.80-1.45) was associated with increased mortality. In multivariable logistic regression, either with propensity adjustment or without, aprotinin was independently predictive of 5-year mortality (adjusted odds ratio with propensity adjustment, 1.48; 95% confidence interval, 1.13-1.93; P = .005) among patients with diverse risk profiles, as well as among those surviving their index hospitalization. Neither aminocaproic nor tranexamic acid was associated with increased risk of death.
Conclusions These findings indicate that in addition to the previously reported acute renal and vascular safety concerns, aprotinin use is associated with an increased risk of long-term mortality following CABG surgery. Use of aprotinin among patients undergoing CABG surgery does not appear prudent because safer and less expensive alternatives (ie, aminocaproic acid and tranexamic acid) are available.
Author Affiliations: Ischemia Research and Education Foundation, San Bruno, Calif (Drs Mangano, Miao, Titov, and Dietzel); Department of Anesthesia, Papworth Hospital, Cambridge, England (Dr Vuylsteke); Department of Anesthesia, Escorts Heart Institute, New Delhi, India (Dr Juneja); Department of Cardiac Anesthesia and Intensive Care, Institute of Cardiology, Bucharest, Romania (Dr Filipescu); Klinik und Poliklinik für Anaesthesiologie und Spezielle Intensivmedizin, University of Bonn, Bonn, Germany (Dr Hoeft); Department of Anesthesiology, Yale University, New Haven, Conn (Dr Fontes); Department of Cardiac Anesthesia, St Luke's Roosevelt Hospital, New York, NY (Dr Hillel); Institut für Anaesthesiologie, Ludwig-Maximilians Universität, Munich, Germany (Dr Ott); Department of Laboratory Medicine, University of California School of Medicine, San Francisco (Dr Levin). Dr Tudor is now with ALZA Corporation, Mountain View, Calif, and Dr Fontes is now with Weill Medical College of Cornell University, New York, NY.
RELATED LETTERS
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Elke Scharnetzky, Walter Schill, and Edeltraut Garbe
JAMA. 2007;297(22):2475.
EXTRACT
| FULL TEXT
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Steven G. Coca and Chirag R. Parikh
JAMA. 2007;297(22):2475-2476.
EXTRACT
| FULL TEXT
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Jeffrey Shuhaiber
JAMA. 2007;297(22):2476.
EXTRACT
| FULL TEXT
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Robert H. Habib, Anoar Zacharias, and Thomas A. Schwann
JAMA. 2007;297(22):2476-2477.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Aprotinin—Are There Lessons Learned?
T. Bruce Ferguson, Jr
JAMA. 2007;297(5):527-529.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Aprotinin Story -- Is BART the Final Chapter?
Ray and Stein
NEJM 2008;0:NEJMe0803514v1-1.
FULL TEXT
A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery
Fergusson et al.
NEJM 2008;0:NEJMoa0802395v1-1.
ABSTRACT
| FULL TEXT
The inflammatory effect of cardiopulmonary bypass on leukocyte extravasation in vivo.
Evans et al.
J. Thorac. Cardiovasc. Surg. 2008;135:999-1006.
ABSTRACT
| FULL TEXT
The Year in Cardiovascular Surgery
Jones
J Am Coll Cardiol 2008;51:1707-1718.
FULL TEXT
Update in Critical Care 2007
Fowler et al.
Am. J. Respir. Crit. Care Med. 2008;177:808-819.
FULL TEXT
The demise of aprotinin: Our share of the blame.
Sundt
J. Thorac. Cardiovasc. Surg. 2008;135:729-731.
FULL TEXT
Observational evidence for determining drug safety
Freemantle and Irs
BMJ 2008;336:627-628.
FULL TEXT
Ethics, Industry, and Outcomes
Merry
SEMIN CARDIOTHORAC VASC ANESTH 2008;12:7-11.
ABSTRACT
Aprotinin and Cardiac Surgery
DeAnda
J. Thorac. Cardiovasc. Surg. 2008;135:492-494.
FULL TEXT
Bleeding in cardiac surgery: The use of aprotinin does not affect survival
Pagano et al.
J. Thorac. Cardiovasc. Surg. 2008;135:495-502.
ABSTRACT
| FULL TEXT
High-dose aprotinin effectively reduces blood loss during on-pump coronary artery bypass grafting with bivalirudin anticoagulation
Koster et al.
J. Thorac. Cardiovasc. Surg. 2008;135:685-687.
FULL TEXT
Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death
Schneeweiss et al.
NEJM 2008;358:771-783.
ABSTRACT
| FULL TEXT
The Effect of Aprotinin on Outcome after Coronary-Artery Bypass Grafting
Shaw et al.
NEJM 2008;358:784-793.
ABSTRACT
| FULL TEXT
Learning from Aprotinin -- Mandatory Trials of Comparative Efficacy and Safety Needed
Ray
NEJM 2008;358:840-842.
FULL TEXT
Aprotinin is safe in pediatric patients undergoing cardiac surgery.
Backer et al.
J. Thorac. Cardiovasc. Surg. 2007;134:1421-1428.
ABSTRACT
| FULL TEXT
RIFLE criteria for acute kidney injury in aortic arch surgery.
Arnaoutakis et al.
J. Thorac. Cardiovasc. Surg. 2007;134:1554-1561.
ABSTRACT
| FULL TEXT
Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome?
Van der Linden et al.
Br J Anaesth 2007;99:646-652.
ABSTRACT
| FULL TEXT
Abstract 1851: Safety of Aprotinin in CABG Patients: Results of the VA MultiCenter Prospective Randomized ROOBY Trial
Zenati et al.
Circulation 2007;116:II_396-II_396.
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery)
Fleisher et al.
Circulation 2007;116:e418-e499.
FULL TEXT
Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action
McEvoy et al.
Anesth. Analg. 2007;105:949-962.
ABSTRACT
| FULL TEXT
Prevention and Treatment of Major Blood Loss
Szabo et al.
NEJM 2007;357:1260-1261.
FULL TEXT
Invited commentary
Levy and Force
Ann. Thorac. Surg. 2007;84:986-987.
FULL TEXT
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Scharnetzky et al.
JAMA 2007;297:2475-2475.
FULL TEXT
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Shuhaiber
JAMA 2007;297:2476-2476.
FULL TEXT
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Coca and Parikh
JAMA 2007;297:2475-2476.
FULL TEXT
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery
Habib et al.
JAMA 2007;297:2476-2477.
FULL TEXT
Valid Comparisons of Antifibrinolytic Agents Used in Cardiac Surgery
Bridges
Circulation 2007;115:2790-2792.
FULL TEXT
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
Brown et al.
Circulation 2007;115:2801-2813.
ABSTRACT
| FULL TEXT
JournalScan
Lindsay
Heart 2007;93:773-774.
FULL TEXT
Coronary artery bypass graft surgery care globalization: The impact of national care on fatal and nonfatal outcome
Ott et al.
J. Thorac. Cardiovasc. Surg. 2007;133:1242-1251.
ABSTRACT
| FULL TEXT
Safety Concerns Persist About Aprotinin
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT
Aprotinin--Are There Lessons Learned?
Ferguson
JAMA 2007;297:527-529.
FULL TEXT
|
